申请人:Takeda Pharmaceutical Company Limited
公开号:US20160264536A1
公开(公告)日:2016-09-15
The problem of the present invention is to provide a compound having a PDE2A inhibitory action, and useful as a prophylactic or therapeutic drug for schizophrenia, Alzheimer's disease and the like. The present invention relates to a compound represented by the formula (I):
wherein each symbol is as described in the DESCRIPTION, or a salt thereof.
本发明的问题是提供一种具有PDE2A抑制作用的化合物,可用作预防或治疗精神分裂症、阿尔茨海默病等疾病的药物。本发明涉及一种由式(I)表示的化合物:其中每个符号如在说明书中所述,或其盐。